EVAR术后低死亡率支持将其应用扩展至高危患者
基于2005至2013年ACS NSQIP数据库24813例EVAR患者,按EVAR 2标准分为高危(至少一项肾、呼吸或心脏受损标准)和低危。高危组30天死亡率为1.9%,远低于EVAR 2报告的7.3%,但仍高于低危组的0.9%(P<.001)。肾脏标准使死亡风险增加三倍以上(OR 3.42)。
要点
- 当代高危患者EVAR术后30天死亡率为1.9%,显著低于EVAR 2的7.3%。
- 肾脏受损标准使30天死亡风险增加三倍以上(OR 3.42)。
- 高危患者经审慎评估后仍可考虑确定性EVAR治疗。
核心结论
- 当代高危患者EVAR术后30天死亡率显著低于EVAR 2试验报告的水平。
- 按现有合并症标准进行低危和高危分层是合适的,但需关注肾脏疾病对死亡率的 disproportionately 高风险贡献。
研究设计与样本
- 回顾性队列研究,数据来自2005至2013年美国外科医师学会国家外科质量改进计划(ACS NSQIP)参与用户数据文件,共纳入24813例接受EVAR的患者。
- 采用EVAR 2试验的患者风险分层标准,将患者分为高危组(至少一项肾、呼吸或心脏术前标准)和低危组。
- 比较两组30天术后结局,分类变量用Pearson χ2检验,连续变量用Wilcoxon秩和检验。
主要发现
- 24813例EVAR患者中,12043例(48%)为高危,12770例(52%)为低危。
- 高危组30天死亡率为1.9%,低危组为0.9%,差异有统计学意义(P < .001)。
- 呼吸标准使30天死亡风险增加(OR 1.62;95% CI 1.16-2.26;P = .005)。
- 心脏标准使30天死亡风险增加(OR 1.55;95% CI 1.14-2.10;P = .005)。
- 肾脏标准使30天死亡风险增加三倍以上(OR 3.42;95% CI 2.31-5.09;P < .001)。
关键数值与推荐
- 肾脏受损标准:透析和肌酐浓度 >2.26 mg/dL。
- 呼吸受损标准:慢性阻塞性肺疾病史和术前呼吸机支持。
- 心脏受损标准:心肌梗死史、充血性心力衰竭、心绞痛和既往冠状动脉介入治疗。
- 高危组30天死亡率为1.9%,低危组为0.9%(P < .001)。
- 肾脏标准OR 3.42(95% CI 2.31-5.09;P < .001),呼吸标准OR 1.62(95% CI 1.16-2.26;P = .005),心脏标准OR 1.55(95% CI 1.14-2.10;P = .005)。
临床怎么用
- 当代数据下高危患者EVAR术后30天死亡率较低,高危分层患者应经审慎评估后考虑确定性EVAR。
- 术前评估应特别关注肾脏疾病,因其对30天死亡风险的贡献显著高于心脏和呼吸合并症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The 2010 endovascular aneurysm repair (EVAR) trial 2 (EVAR 2) reported that patients with comorbidity profiles rendering them unfit for open aneurysm repair who underwent EVAR did not experience a survival advantage compared with those who did not undergo intervention. These patients experienced a 30-day mortality of 7.3%, whereas reports from similar cohorts reported far lower mortality rates. The primary objective of our study was to compare the incidence of 30-day mortality in low- and high-risk patients undergoing EVAR in a contemporary data set, using patient risk stratification criteria from EVAR 2. Secondarily, we sought to identify risk factors associated with a disproportionate contribution to 30-day mortality risk. METHODS: Data were obtained from the 2005 to 2013 American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) Participant Use Data Files (N = 24,813). Patients were included in the high-risk cohort with the presence of renal, respiratory, or cardiac preoperative criteria alone or in combination. Renal impairment criteria were defined as dialysis and creatinine concentration >2.26 mg/dL. Respiratory impairment criteria included history of chronic obstructive pulmonary disease and preoperative ventilator support. Cardiac impairment criteria included history of myocardial infarction, congestive heart failure, angina, and prior coronary intervention. Patient and procedural characteristics and 30-day postoperative outcomes were compared using Pearson χ2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables. RESULTS: Among 24,813 patients undergoing EVAR, 12,043 (48%) patients were characterized as high risk (at least one impairment criterion); 12,770 (52%) patients were stratified as low risk. The 30-day mortality rate was 1.9% in the high-risk cohort compared with the 7.3% reported by EVAR 2, and it was higher in the high-risk cohort compared with the low-risk cohort (1.9% vs 0.9%; P < .001). Whereas the presence of each comorbidity increased the odds of 30-day mortality (respiratory odds ratio [OR], 1.62; 95% confidence interval [CI], 1.16-2.26; P = .005; cardiac OR, 1.55; 95% CI, 1.14-2.10; P = .005), the presence of renal criteria disproportionately increased the odds of mortality threefold (OR, 3.42; 95% CI, 2.31-5.09; P < .001). CONCLUSIONS: Contemporary 30-day mortality after EVAR in high-risk patients is substantially lower than that reported in the EVAR 2 trial. Whereas low- and high-risk stratification by current comorbidity criteria is appropriate, attention needs to be paid to disproportionate risk contribution from renal disease to mortality compared with cardiac and pulmonary comorbidities. Given the lower mortality risk than previously described, patients stratified as high risk should be thoughtfully considered for definitive EVAR.
引用
- Adkar SS, Turner MC, Leraas HJ, et al. Low mortality rates after endovascular aortic repair expand use to high-risk patients. J Vasc Surg. 2017. PMID: 28951155. doi:10.1016/j.jvs.2017.06.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。